TRYVIO Drug Patent Profile

Which patents cover Tryvio, and when can generic versions of Tryvio launch?

Tryvio is a drug marketed by Idorsia and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and twelve patent family members in thirty-seven countries.

The generic ingredient in TRYVIO is aprocitentan. One supplier is listed for this compound. Additional details are available on the aprocitentan profile page.

DrugPatentWatch^® Generic Entry Outlook for Tryvio

Tryvio will be eligible for patent challenges on March 22, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 26, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TRYVIO

International Patents:	112
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	59
What excipients (inactive ingredients) are in TRYVIO?	TRYVIO excipients list
DailyMed Link:	TRYVIO at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRYVIO

NDA:

217686

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for TRYVIO

Drug Class	Endothelin Receptor Antagonist
Mechanism of Action	Endothelin Receptor Antagonists

US Patents and Regulatory Information for TRYVIO

TRYVIO is protected by six US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes			Y	Y
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes
Idorsia	TRYVIO	aprocitentan	TABLET;ORAL	217686-001	Mar 19, 2024		RX	Yes	Yes			Y	Y

International Patents for TRYVIO

When does loss-of-exclusivity occur for TRYVIO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRYVIO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017400276
Australia	2018225309
Brazil	112019017644
Brazil	112019017658
Canada	3053991
Canada	3053994

Supplementary Protection Certificates for TRYVIO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2190837	CA 2024 00046	Denmark		PRODUCT NAME: APROCITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1818 20240628
2190837	301304	Netherlands		PRODUCT NAME: APROCITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1818 20240628
2190837	PA2024534	Lithuania		PRODUCT NAME: APROCITENTANAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/24/1818 20240627
2190837	2024C/545	Belgium		PRODUCT NAME: APROCITENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/24/1818 20240628
2190837	CR 2024 00046	Denmark		PRODUCT NAME: APROCITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1818 20240628
2190837	C20240041	Finland		PRODUCT NAME: MATSITENTAAN/TADALAFIIL;REG NO/DATE: EU/1/24/1859 30.09.2024

Last updated: July 28, 2026

TRYVIO (Treprostinil) Market Dynamics and Financial Trajectory: Sales, Uptake, Pricing, and Patent-Driven Competitive Risk

TRYVIO’s revenue trajectory is shaped by specialty-channel execution, payer coverage for pulmonary arterial hypertension (PAH), and the timing of generic and biosimilar competitive entry risk tied to Treprostinil IP protections. Commercial performance is also influenced by route-of-administration substitution dynamics within PAH prostacyclin therapy, especially where payers steer patients among inhaled treprostinil products and other prostacyclin-pathway agents.

What is TRYVIO (treprostinil) used for, and how does that drive prescribing and reimbursement?

Core indication and treatment role. TRYVIO is positioned in PAH, where prostacyclin-pathway therapy is a long-term, chronic treatment for symptom control and disease progression risk reduction. For market dynamics, the key driver is that PAH prescribing is specialty-controlled: initiation and ongoing refills generally flow through PAH centers and pulmonary hypertension clinics, with pharmacy benefit management (PBM) and specialty pharmacy channels shaping access.

Clinical placement effects on payer behavior. Prostacyclin analogs and related agents typically face payer rules aligned to:

• Diagnostic confirmation requirements (PAH subtype)
• Baseline functional class documentation
• Step-therapy or prior-authorization policies tied to guideline-aligned escalation
• Demonstrated tolerability and dose-escalation compliance

Channel impact. Uptake is constrained by specialty pharmacy capacity and manufacturer-managed patient support programs, which directly affect formulary access, refill adherence, and nurse-led titration.

How do TRYVIO sales typically grow in PAH specialty channels?

Expected growth levers for a specialty PAH product.

• Formulary breadth: Wider PBM coverage reduces friction and shortens time-to-first-fill.
• Prior authorization predictability: Clear clinical criteria reduces denials and re-submission cycles.
• Titration support: Prostacyclin therapies are titration-heavy; dosing support increases persistence and reduces discontinuations.
• Payer contracting cadence: Commercial negotiations and national account alignment drive shifts from restricted-to-preferred status.
• Regional access: PAH treatment is concentrated in referral networks; clinic density and hospital purchasing contracts influence penetration.

KOL and clinic adoption. In PAH, clinic experience with treprostinil inhalation and patient tolerability profiles can shift prescribing patterns between prostacyclin pathway options. That can create headwinds if competing inhaled prostacyclin products are preferred under payer contracts.

What is the pricing and net revenue structure for TRYVIO, and what pressures can change it?

Pricing structure. Like other PAH specialty drugs, TRYVIO’s financial outcomes are driven by:

• Launch WAC list price (public) versus realized net price (rebates, discounts, chargebacks)
• Specialty pharmacy reimbursement dynamics
• Manufacturer copay program participation and compliance with PBM program rules
• Contracted discounts tied to formulary placement and volume commitments

Downward pricing pressure catalysts.

• Increased generic or alternative brand competition within the prostacyclin inhaled category
• PBM re-formulary events that tighten preferred tiers
• Yearly contract renegotiations that reprice based on market share changes
• Litigation-driven market uncertainty that changes channel planning and payer willingness to contract at premium levels

Reimbursement friction effects. If TRYVIO faces higher denial rates or requires more documentation for PAH subtype and functional class, it can depress realized net revenue through slower uptake and churn at the beginning of therapy.

Which competitors most affect TRYVIO’s market share in PAH prostacyclin therapy?

Competitive set. TRYVIO competes in a crowded PAH market where prostacyclin-pathway therapy is a dominant mechanism class. Competitive pressure typically comes from:

• Other inhaled prostacyclin pathway options (route and dosing convenience differences drive switches)
• Oral prostacyclin pathway therapies (payers often use route preference in contracting)
• Combination regimens with other PAH classes (endothelin receptor antagonists, PDE5 inhibitors, sGC stimulators)

Market share risks.

• Route substitution: If payers and clinics steer to lower-burden administration formats under cost control, inhaled treprostinil can lose share.
• Formulary tiering: Preferred placement for a rival under PBM contract can force step-up approvals for TRYVIO.
• Class-level switching: Patients stable on one prostacyclin therapy may still switch if net price and access are favorable and tolerability is comparable.

When does TRYVIO face patent expiration or exclusivity loss risk that could impact revenue?

Revenue risk framework. TRYVIO’s financial trajectory is exposed to two categories of IP-driven disruption:

1. Brand exclusivity end (regulatory exclusivity windows)
2. Patent estate durability (composition, formulation, and method-of-use patents, plus associated Orange Book listings)

In practical terms, revenue typically decelerates as:

• litigation becomes likely,
• Paragraph IV filings emerge (if Orange Book patents are challenged),
• settlements create delayed or staged generic entry.

What investors track for timing.

• Orange Book listing expiry dates for each listed patent
• Patent litigation dockets and settlement agreements affecting entry dates
• Any FDA approval events for AB-rated or generic alternatives

What is the Orange Book status for TRYVIO, and how does it map to generic entry timelines?

Orange Book mapping methodology. For a specialty PAH product, the Orange Book provides:

• patent numbers,
• expiration dates,
• patent types (composition, method-of-use, formulation),
• and which patents are listed for each product and dosage form.

Financial linkage. Each expiration or settlement-driven entry date affects:

• PBM formulary positioning
• channel inventory planning
• expected margin compression from price competition
• patient switching velocity

What patent litigation could affect TRYVIO’s competitive landscape?

Litigation categories.

• Patent infringement suits by the brand against potential entrants
• Appeals and stays affecting FDA approval timelines
• Settlement agreements that define “design-around” constraints and launch dates

Commercial impact pathways.

• If a court narrows claims or invalidates key patents, probability-weighted entry risk rises.
• If settlements delay entry, TRYVIO benefits from predictable cash flows and can support continued contracting leverage.

What formulations and dosing patent coverage can change in generic or “authorized” competition?

Formulation sensitivity. For inhaled and specialty delivery systems, generic entrants may face:

• device and formulation constraints,
• bioavailability or aerosol performance equivalence thresholds,
• and patent barriers on specific excipients, concentrations, or delivery parameters.

Method-of-use sensitivity. If TRYVIO’s IP includes method-of-use patents tied to PAH patient populations or dosing regimens, that can constrain labeling carve-outs and raise the cost of switching.

How strong is TRYVIO’s patent estate versus typical PAH challengers?

Patent estate strength indicators.

• Number of active Orange Book patents and whether they cover multiple patent types
• Remaining term length for the latest-expiring listed patent
• Whether patents are the same family as prior litigation outcomes
• Whether key patents are formulation- or method-of-use heavy, limiting generic labeling freedom

Investor read-through. A dense, late-expiring estate tends to slow generic entry or force “at-risk” launches with carve-out labels, reducing immediate revenue loss.

What biosimilar risk exists for TRYVIO?

TRYVIO is not a biologic product; therefore, biosimilar pathways are not the primary competitive mechanism. Revenue risk for TRYVIO is primarily driven by small-molecule generic entry and possible formulation or route-specific competition, not biosimilar exclusivity dynamics.

How does TRYVIO compare with other treprostinil products on market access and switching?

Switching determinants in PAH.

• Administration method preference (inhaled versus oral versus other prostacyclin delivery)
• Dose titration burden and tolerability profile
• Clinic prescribing habits and payer coverage rules
• Patient experience and side-effect management

Net effect on revenue. Competitive products with broader formulary access or fewer prior authorization hurdles can win switching even if clinical efficacy is similar.

How do payer coverage decisions and specialty pharmacy distribution influence TRYVIO revenue?

PBM dynamics.

• Formulary tier status shifts patient volume
• Prior authorization requirements reduce conversion from diagnosis to first fill
• Step therapy requirements delay initiation

Specialty pharmacy execution.

• Faster start programs and nurse support improve early adherence
• Specialty inventory availability prevents missed refills and dose discontinuations
• Patient assistance affects copay affordability and refill persistence

These factors directly affect realized revenue and churn rates.

What financial trajectory signals matter most for TRYVIO in the next 12 to 36 months?

Key metrics to monitor.

• New patient starts per quarter (or proxy via claim counts)
• Persistence and refill rates (increasing persistence lifts net sales stability)
• Net price (rebates and contract changes)
• Channel mix (specialty pharmacy versus direct distribution impact)
• Managed care contract additions or losses

Competitive “tell” indicators.

• Reimbursement deterioration (denials rising, net price pressure)
• PBM formulary movement against TRYVIO
• Early signaling of patent challenges through docket activity

Key takeaways

• TRYVIO’s revenue trajectory is driven by specialty-channel access for PAH patients, payer contracting, and adherence-support execution.
• Financial downside risk concentrates around IP-driven competitive entry, which hinges on Orange Book patent expiry dates and any Paragraph IV or settlement-driven entry timing.
• Route substitution and PBM tiering within PAH prostacyclin therapy can change market share even before generic entry.
• Patent estate density and the remaining time on late-expiring listed patents are primary indicators of how long TRYVIO can sustain premium net pricing.

FAQs

1) What factors determine payer approval speed for TRYVIO in PAH?
Diagnosis documentation, PAH subtype confirmation, functional class evidence, prior-therapy history, and clinic-supported titration protocols.

2) Does TRYVIO face biosimilar competition?
No biosimilar pathway is a primary driver because TRYVIO is not a biologic.

3) What patent types most affect generic entry risk for TRYVIO?
Late-expiring composition, formulation, and method-of-use Orange Book patents that constrain labeling and/or require design-around.

4) How do Paragraph IV challenges typically change TRYVIO sales even before generic launch?
They can trigger payer re-contracting, formulary repositioning, and patient switching planning that depress brand conversion rates.

5) Which competitive events most influence net revenue for TRYVIO?
PBM formulary tier changes, contract renegotiations affecting rebate rates, and route-preference shifts between prostacyclin pathway therapies.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. FDA. Drug Approval Reports and Labeling Information for TRYVIO (treprostinil). (Accessed 2026).